THE ROLE OF SSA AT PROGRESSION
TO CONTINUE OR NOT?

CLINICAL TAKEAWAYS

Potential patient groups and treatment strategies

- In patients with well-differentiated Grade 1/2 NETS and slowly progressive asymptomatic disease, the following strategies could be potential considerations in selected patients
  - Increase the SSA dose (increase frequency from 4 weeks to 2 weeks)
  - Increase the monthly dose of SSA
- SSA as maintenance (after stopping chemotherapy [for toxicity concerns] in stable patients)
- Patients receiving PRRT (during and/or post-PRRT)

Therapies approved for the treatment of NETs[1]



Clinical evidence for continuing SSAs on progression

PROSPECTIVE STUDIES

NETTER-1[2]	CLARINET FORTE[3]	REMINET[4]
All study patients continued high dose octreotide (60 mg every 4 weeks) regardless of functional status	Reducing lanreotide autogel dosing interval (from every 4 weeks to every 2 weeks) provided clinically meaningful PFS with no safety concerns	Maintenance lanreotide autogel treatment provided encouraging efficacy results and reduced toxicity

RETROSPECTIVE ANALYSES

- Significantly better outcomes with SSA + PRRT vs PRRT alone[5]
- High-dose SSA (increased administered dose or shortened interval between administrations) shown to be an active treatment option with no safety concerns[6]

NET connect® POWERED BY COR2ED

1. Chauhan A, et al. Cancers 2022;14:5248 2. Strosberg, et al. N Engl J Med 2017;376:125-35; 3. Pavel M, et al. Eur J Cancer. 2021;157:403-14; 4. Lepage C, et al. Eur J Cancer. 2022;175:31-40; 5. Yordanova A, et al. Clin Cancer Res. 2018;24:4672-79; 6. Lamberti G, et al. J Clin Endocrinol Metab. 2020;105:dgz035

177Lu, lutetium-177; GEP, gastroenteropancreatic; NET, neuroendocrine tumour; pNET, pancreatic neuroendocrine tumour; PFS, progression-free survival; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analogue

The programme is supported by an independent educational grant from Ipsen. The programme is therefore independent; the content is not influenced by the supporter and is under the sole responsibility of the experts.

Go to COR2ED.COM for more information and resources

December 2022